Breast care (Basel, Switzerland)最新文献

{"title":"ASCO 2020.","authors":"Rupert Bartsch, Veronique Dieras, Javier Cortes, Volkmar Müller, Thomas Ruhstaller","doi":"10.1159/000510051","DOIUrl":"https://doi.org/10.1159/000510051","url":null,"abstract":"a Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria; b Centre Eugène-Marquis, Rennes, France; c IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; d Department of Obstetrics and Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; e Breast Center Eastern Switzerland, St. Gallen, Switzerland Received: July 6, 2020 Accepted: July 6, 2020 Published online: July 16, 2020","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"433-436"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000510051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000502368","DOIUrl":"https://doi.org/10.1159/000502368","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000499534.].</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"102"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000502368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37787230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel.","authors":"Tal Sella,&nbsp;Gabriel Chodick","doi":"10.1159/000500318","DOIUrl":"https://doi.org/10.1159/000500318","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant hormonal therapy (HT) has been consistently proven to improve multiple outcomes in early breast cancer yet rates of adherence and persistence are variable.</p><p><strong>Methods: </strong>We retrospectively identified women diagnosed with nonmetastatic breast cancer and initiating HT between January 2000 and December 2007 in a large Israeli health provider. Prescription records including the drug name, date of purchase, and the quantity of pills dispensed were collected. We used Cox proportional hazards and binary logistic models to analyze factors associated with early discontinuation (<5 years) and nonadherence (proportion of days covered, PDC <80%) of HT, respectively.</p><p><strong>Results: </strong>A total of 4,178 women with breast cancer were identified with nearly 95% of patients treated with tamoxifen as the initial HT. Over the 5-year follow-up period, early discontinuation was identified in 955 (23%) patients. The mean PDC was 82.9% (SD 0.004). Younger age and low BMI were both associated with an increased risk of early discontinuation and nonadherence. A history of hypertension was associated with a higher likelihood of both outcomes.</p><p><strong>Conclusion: </strong>Adherence and persistence with HT among Israeli breast cancer survivors are comparable to those in international reports. Interventions are necessary to identify and prevent suboptimal HT adherence.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"45-53"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000500318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37787260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights from ABC5: Bridging the Gap.","authors":"Rachel Wuerstlein,&nbsp;Carlos Barrios,&nbsp;Matteo Lambertini,&nbsp;Janice Tsang,&nbsp;Joana M Ribeiro,&nbsp;Renate Haidinger","doi":"10.1159/000505900","DOIUrl":"https://doi.org/10.1159/000505900","url":null,"abstract":"a Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU) and CCC Munich LMU, Munich, Germany; b Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil; c Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; d Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy; e Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Breast Oncology Group, Hong Kong, Hong Kong SAR; f Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal; g Brustkrebs Deutschland e.V., Hohenbrunn, Germany Received: December 30, 2019 Accepted: January 14, 2020 Published online: February 7, 2020","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"75-81"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000505900","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37787264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.","authors":"Marina Elena Cazzaniga,&nbsp;Claudio Verusio,&nbsp;Mariangela Ciccarese,&nbsp;Alberto Fumagalli,&nbsp;Donata Sartori,&nbsp;Maria Rosaria Valerio,&nbsp;Mario Airoldi,&nbsp;Gabriella Moretti,&nbsp;Corrado Ficorella,&nbsp;Lorenzo Gianni,&nbsp;Andrea Michelotti,&nbsp;Alberto Zambelli,&nbsp;Antonio Febbraro,&nbsp;Daniele Generali,&nbsp;Mirco Pistelli,&nbsp;Ornella Garrone,&nbsp;Antonino Musolino,&nbsp;Patrizia Vici,&nbsp;Michela Maur,&nbsp;Lucia Mentuccia,&nbsp;Nicla La Verde,&nbsp;Giulia Valeria Bianchi,&nbsp;Salvatore Artale,&nbsp;Livio Blasi,&nbsp;Michelino De Laurentiis,&nbsp;Francesco Atzori,&nbsp;Anna Turletti,&nbsp;Mauro Porpiglia,&nbsp;Daniele Santini,&nbsp;Alessandra Fabi,&nbsp;Vittorio Gebbia,&nbsp;Alessio Schirone,&nbsp;Raffaella Palumbo,&nbsp;Antonella Ferzi,&nbsp;Antonio Frassoldati,&nbsp;Claudio Scavelli,&nbsp;Luca Clivio,&nbsp;Monica Giordano,&nbsp;Michela Donadio,&nbsp;Laura Biganzoli,&nbsp;Lucia Del Mastro,&nbsp;Giancarlo Bisagni,&nbsp;Lorenzo Livi,&nbsp;Clara Natoli,&nbsp;Filippo Montemurro,&nbsp;Ferdinando Riccardi,&nbsp;Emanuela Romagnoli,&nbsp;Paolo Marchetti,&nbsp;Valter Torri,&nbsp;Paolo Pronzato,&nbsp;Giorgio Mustacchi","doi":"10.1159/000495469","DOIUrl":"https://doi.org/10.1159/000495469","url":null,"abstract":"<p><strong>Background: </strong>Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting.</p><p><strong>Methods: </strong>For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies).</p><p><strong>Results: </strong>Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively.</p><p><strong>Conclusion: </strong>These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"30-37"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000495469","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37787259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620.","authors":"Michael Untch,&nbsp;Sibylle Loibl,&nbsp;Peter A Fasching","doi":"10.1159/000500624","DOIUrl":"https://doi.org/10.1159/000500624","url":null,"abstract":"","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"96-101"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000500624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37787265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient.","authors":"Hugo Herrscher,&nbsp;Julie Leblanc,&nbsp;Thierry Petit","doi":"10.1159/000500708","DOIUrl":"https://doi.org/10.1159/000500708","url":null,"abstract":"<p><strong>Background: </strong>The main side effects of tamoxifen are menopausal symptoms. We report a case of agranulocytosis induced by tamoxifen in a 33-year-old woman treated in the adjuvant setting.</p><p><strong>Case presentation: </strong>Ten days after the beginning of tamoxifen treatment, the patient complained of asthenia and mucositis. Blood testing showed a grade 4 neutropenia (0.06 G/L) without any other major hematologic disorder. Tamoxifen was discontinued, and the patient received granulocyte colony-stimulating factor. Within 2 days, she recovered to a normal granulocyte count. Tamoxifen was then switched to the combination of ovarian suppression (triptorelin) and aromatase inhibitor (anastrozole).</p><p><strong>Conclusion: </strong>Agranulocytosis is a very rare adverse event of tamoxifen.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"72-74"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000500708","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37787263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living with Male Breast Cancer: A Qualitative Study of Men's Experiences and Care Needs.","authors":"Truc Sophia Nguyen,&nbsp;Maret Bauer,&nbsp;Nicolai Maass,&nbsp;Hanna Kaduszkiewicz","doi":"10.1159/000501542","DOIUrl":"https://doi.org/10.1159/000501542","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) is rare, and most previous studies limited their focus on clinical aspects of the disease. Psychosocial implications and care needs of MBC patients are poorly understood.</p><p><strong>Objectives: </strong>The aim of this study is to explore the experiences of men living with breast cancer and to identify supportive care needs.</p><p><strong>Methods: </strong>Eighteen men were interviewed using qualitative, semi-structured telephone interviews. Qualitative content analysis was used to analyze the data.</p><p><strong>Results: </strong>The majority of men did not have negative feelings about having a \"women's disease,\" although some felt that stigmatization threatened their masculinity. Male sex was perceived as hindering access to adequate care. Patients identified key barriers including (1) a lack of awareness and experience of treating males among health professionals; (2) treatment and available information were based on evidence for females; and (3) lacking support services.</p><p><strong>Conclusion: </strong>To improve MBC care, it is important to raise awareness of the disease and to adapt treatment strategies, patient information, and support services to meet the needs of men.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"6-12"},"PeriodicalIF":2.1,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000501542","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37788927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial.","authors":"Sibylle Loibl,&nbsp;Gabriele Doering,&nbsp;Lothar Müller,&nbsp;Albert Grote-Metke,&nbsp;Roberto Müller,&nbsp;Oliver Tomé,&nbsp;Wolfgang Wiest,&nbsp;Andrea Maisch,&nbsp;Valentina Nekljudova,&nbsp;Gunter von Minckwitz","doi":"10.1159/000335199","DOIUrl":"https://doi.org/10.1159/000335199","url":null,"abstract":"<p><p>The combination of bendamustine (B) and paclitaxel (P) as anthracycline-free treatment option in patients with advanced breast cancer has been evaluated in the previous RiTa I trial. The regimen of weekly B 70 mg/m(2) and P 90 mg/m(2) with a pause every 4th week was established as an effective regimen with low toxicity. The aim of the present RiTa II study was to investigate the potential of BP as anthracycline-free combination therapy. The primary objective was to determine the progression-free survival (PFS); secondary endpoints were safety, tolerability, overall response rate (ORR) and overall survival (OS). 26 patients were available, 15 received BP as first-line, 11 as beyond first-line treatment. 27% patients had triple-negative breast cancer (TNBC). Median PFS and OS were 7.3 months (95% confidence interval (CI): 5.5-10.9) and 14.9 months (95% CI: 9.9-22.9), respectively. The 1-year PFS rate was 20.3% and the 1-year OS rate 71.2%. The ORR was 42.3%, including 4 complete and 7 partial remissions. TNBC patients reached an ORR of 71.4%. Anthracycline-pretreated patients showed an ORR of 43.8%, confirming bendamustine's lack of cross-resistance to anthracycline agents. BP represents a favorable option with moderate toxicity in pretreated metastatic breast cancer and offers a possibility for application in anthracycline-pretreated and TNBC patients.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"457-461"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000335199","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40166612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Clinical Features and Treatment Outcome of Breast Cancers in Young and Elderly Chinese Patients.","authors":"Jun Tang,&nbsp;Chu-Cheng Wu,&nbsp;Ze-Ming Xie,&nbsp;Rong-Zhen Luo,&nbsp;Ming-Tian Yang","doi":"10.1159/000332593","DOIUrl":"https://doi.org/10.1159/000332593","url":null,"abstract":"<p><p>BACKGROUND: This study aimed to investigate the clinicopathological features and prognosis of operable breast cancers in young and elderly Chinese women. PATIENTS AND METHODS: This study included 209 patients aged ≤35 years and 213 patients aged ≥60 but <70 years, who received treatment between January 2000 and December 2004. The clinicopathological features, molecular subtypes, therapeutic strategies, and prognosis were evaluated. RESULTS: Tumor size was of significant difference between the 2 groups (p = 0.018), with more T2 and T3 tumors in the young group and more lymph node involvement in young patients with stage T1 tumors (p = 0.033). There were more triple-negative and less luminal A tumors in the young group (p = 0.018). 47.1% of tumors were not detected by mammography in the young group as compared to 5.5% in the elderly group (p < 0.001). More patients received chemotherapy in the young group (p < 0.001) and preferred breast-conserving surgery (p = 0.031). The 6-year disease-free survival (DFS) was 80 and 66% in the elderly and the young group, respectively (p = 0.001), but no difference was seen in overall survival. CONCLUSIONS: Compared with elderly women, young breast cancer patients have different clinicopathological features and molecular subtypes, and poorer DFS. Furthermore, the insidious onset of breast cancer in young women suggests that clinicians should pay more attention to young women with breast abnormalities.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"435-440"},"PeriodicalIF":2.1,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000332593","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40167231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}